GERON CORP Other Comprehensive Income (Loss), Net of Tax
GERON CORP (GERN) reported Other Comprehensive Income (Loss), Net of Tax of $162.00 thousand for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-07.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2022-11-07
- GERON CORP other comprehensive income (loss), net of tax for the quarter ending 2022-09-30 was $162.00K, a 1146.15% increase year-over-year.
- GERON CORP other comprehensive income (loss), net of tax for the quarter ending 2022-06-30 was -$71.00K.
- GERON CORP other comprehensive income (loss), net of tax for the quarter ending 2022-03-31 was -$538.00K.
- GERON CORP other comprehensive income (loss), net of tax for the quarter ending 2021-09-30 was $13.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month |
|---|---|---|---|
| 2022-09-30 | $162.00K 10-Q · filed 2022-11-07 | $91.00K derived: sum of 2 quarters · filed 2022-11-07 | -$447.00K derived: sum of 3 quarters · filed 2022-11-07 |
| 2022-06-30 | -$71.00K 10-Q · filed 2022-11-07 | -$609.00K derived: sum of 2 quarters · filed 2022-11-07 | |
| 2022-03-31 | -$538.00K 10-Q · filed 2022-11-07 | ||
| 2021-09-30 | $13.00K 10-Q · filed 2022-11-07 | -$19.00K derived: sum of 2 quarters · filed 2022-11-07 | -$62.00K derived: sum of 3 quarters · filed 2022-11-07 |
| 2021-06-30 | -$32.00K 10-Q · filed 2022-11-07 | -$75.00K derived: sum of 2 quarters · filed 2022-11-07 | |
| 2021-03-31 | -$43.00K 10-Q · filed 2022-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |